The PPARδ agonist GW0742X reduces atherosclerosis in LDLR-/- mice

被引:181
作者
Graham, TL
Mookherjee, C
Suckling, KE
Palmer, CNA
Patel, L [1 ]
机构
[1] GlaxoSmithKline Inc, Dept Atherosclerosis, Cardiovasc & Urol Ctr Excellence Drug Discovery, Stevenage SG1 2NY, Herts, England
[2] Univ Dundee, Biomed Res Ctr, Ninewells Hosp & Med Sch, Dundee DD1, Scotland
[3] GlaxoSmithKline Inc, Dept Drug Metab & Pharmacokinet, Cardiovasc & Urol Ctr Excellence Drug Discovery, Stevenage SG1 2NY, Herts, England
基金
英国生物技术与生命科学研究理事会;
关键词
PPAR delta; LDLR; HDL; VLDL; TNF alpha; macrophage; atherosclerosis;
D O I
10.1016/j.atherosclerosis.2004.12.028
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several lines of evidence suggest a biological role for peroxisome proliferator-activated receptor (PPAR delta) in the pathogenesis of atherosclerosis. Administration of synthetic PPAR delta agonists to obese rhesus monkeys elevates serum high-density lipoprotem (HDL) cholesterol as a result of increased reverse cholesterol transport whilst in vitro studies have suggested a role for PPAR delta in lipid uptake into macrophages. Recent studies have found that PPAR delta depletion from macrophages in LDL receptor (LDLR-/-) mice decreases lesion area via modulation of the inflammatory status of the macrophage, an effect also seen on pharmacological activation of PPAR delta in vitro. We demonstrate here that the PPAR delta agonist, GW0742X has potent anti-atherogenic activity in the LDLR-/- mouse, decreasing lesion area by up to 50%. Administration of GW0742X had no effect on total cholesterol, HDL or LDL cholesterol and modest effects on very low-density lipoprotein (VLDL). Treatment with GW0742X resulted in decreased expression of monocyte chemoattractant protein 1 (MCP-1) and intracellular adhesion moleculae 1 (ICAM-1) in the aortae of treated mice. In addition, GW0742X decreased tumour necrosis factor-alpha (TNF alpha) expression in peritoneal macrophages, aortae and adipose tissue in comparison with control animals. Changes in gene expression were reflected in decreased plasma levels of MCP-1. These observations support an atheroprotective effect of PPAR delta agonists in vivo. (c) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:29 / 37
页数:9
相关论文
共 33 条
[1]   Peroxisome proliferator-activated receptor β/δ regulates very low density lipoprotein production and catabolism in mice on a Western diet [J].
Akiyama, TE ;
Lambert, G ;
Nicol, CJ ;
Matsusue, K ;
Peters, JM ;
Brewer, HB ;
Gonzalez, FJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (20) :20874-20881
[2]   Characterization of the species-specificity of peroxisome proliferators in rat and human hepatocytes [J].
Ammerschlaeger, M ;
Beigel, J ;
Klein, KU ;
Mueller, SO .
TOXICOLOGICAL SCIENCES, 2004, 78 (02) :229-240
[3]   Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation [J].
Bishop-Bailey, D ;
Wray, J .
PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2003, 71 (1-2) :1-22
[4]   Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? [J].
Cattley, RC ;
DeLuca, J ;
Elcombe, C ;
Fenner-Crisp, P ;
Lake, BG ;
Marsman, DS ;
Pastoor, TA ;
Popp, JA ;
Robinson, DE ;
Schwetz, B ;
Tugwood, J ;
Wahli, W .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1998, 27 (01) :47-60
[5]   PPARγ is a very low-density lipoprotein sensor in macrophages [J].
Chawla, A ;
Lee, CH ;
Barak, Y ;
He, WM ;
Rosenfeld, J ;
Liao, D ;
Han, J ;
Kang, H ;
Evans, RM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (03) :1268-1273
[6]   PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation [J].
Chawla, A ;
Barak, Y ;
Nagy, L ;
Liao, D ;
Tontonoz, P ;
Evans, RM .
NATURE MEDICINE, 2001, 7 (01) :48-52
[7]   Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice - Pleiotropic effects on CD36 expression and HDL [J].
Chen, Z ;
Ishibashi, S ;
Perrey, S ;
Osuga, J ;
Gotoda, T ;
Kitamine, T ;
Tamura, Y ;
Okazaki, H ;
Yahagi, N ;
Iizuka, Y ;
Shionoiri, F ;
Ohashi, K ;
Harada, K ;
Shimano, H ;
Nagai, R ;
Yamada, N .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (03) :372-377
[8]   Peroxisome proliferator-activated receptor δ activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes [J].
Cheng, LH ;
Ding, GL ;
Qin, QH ;
Xiao, Y ;
Woods, D ;
Chen, YQE ;
Yang, QL .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 313 (02) :277-286
[9]   Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications [J].
Chinetti, G ;
Fruchart, JC ;
Staels, B .
INTERNATIONAL JOURNAL OF OBESITY, 2003, 27 (Suppl 3) :S41-S45
[10]   Evidence for peroxisome proliferator-activated receptor (PPAR)α-independent peroxisome proliferation:: Effects of PPARγ/δ-specific agonists in PPARα-Null mice [J].
DeLuca, JG ;
Doebber, TW ;
Kelly, LJ ;
Kemp, RK ;
Molon-Noblot, S ;
Sahoo, SP ;
Ventre, J ;
Wu, MS ;
Peters, JM ;
Gonzalez, FJ ;
Moller, DE .
MOLECULAR PHARMACOLOGY, 2000, 58 (03) :470-476